• +1-646-491-9876
    • +91-20-67278686

    Search

    Diarrhea-Pipeline Review H2 2017

    Diarrhea-Pipeline Review H2 2017

    • Report Code ID: RW0001881459
    • Category Life Sciences
    • No. of Pages 146
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Diarrhea-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea-Pipeline Review H2 2017 provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

    Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea abdominal pain cramping bloating dehydration fever bloody stools frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diarrhea-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II Phase I IND/CTA Filed Preclinical and Discovery stages are 7 10 2 1 21 and 4 respectively. Similarly the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules respectively.

    Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal) .
    - The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Diarrhea-Overview 7
    Diarrhea-Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 13
    Products under Development by Companies 14
    Products under Development by Universities/Institutes 17
    Diarrhea-Therapeutics Assessment 18
    Assessment by Target 18
    Assessment by Mechanism of Action 21
    Assessment by Route of Administration 23
    Assessment by Molecule Type 25
    Diarrhea-Companies Involved in Therapeutics Development 27
    A. Menarini Industrie Farmaceutiche Riunite Srl 27
    Actelion Ltd 27
    Aegis Therapeutics LLC 28
    Akthelia Pharmaceuticals Ltd 28
    Albireo Pharma Inc 29
    Allergan Plc 29
    Anatara Lifesciences Limited 30
    Ardelyx Inc 30
    Assembly Biosciences Inc 31
    AzurRx BioPharma Inc 31
    Bharat Biotech International Ltd 32
    Cosmo Pharmaceuticals NV 32
    DiscoveryBiomed Inc 33
    GP Pharm SA 33
    Miyarisan Pharmaceutical Company Ltd 34
    Mucosis BV 34
    Napo Pharmaceuticals Inc 35
    Nippon Shinyaku Co Ltd 35
    Novartis AG 36
    Pfizer Inc 36
    Prokarium Ltd 37
    Rebiotix Inc 37
    Recce Ltd 38
    RedHill Biopharma Ltd 38
    RxBio Inc 39
    Scandinavian Biopharma Holding AB 39
    Sigmoid Pharma Ltd 40
    Summit Therapeutics Plc 40
    Synthetic Biologics Inc 41
    Syntiron LLC 41
    Tasly Pharmaceutical Group Co Ltd 42
    Wuhan Institute of Biological Products Co Ltd 42
    Diarrhea-Drug Profiles 43
    ABIM-101-Drug Profile 43
    AKT-10081-Drug Profile 44
    ASP-7147-Drug Profile 45
    AZX-1101-Drug Profile 46
    Biologic for Irritable Bowel Syndrome with Diarrhea-Drug Profile 47
    cadazolid-Drug Profile 48
    Campylobacter jejuni [strain CPS81-176] vaccine-Drug Profile 50
    CBM-588-Drug Profile 52
    cholestyramine-Drug Profile 54
    crofelemer DR-Drug Profile 56
    Drugs for Irritable Bowel Syndrome with Diarrhea-Drug Profile 60
    Escherichia coli vaccine-Drug Profile 61
    ETEC vaccine-Drug Profile 62
    ETEC vaccine-Drug Profile 63
    Etvax-Drug Profile 64
    GXG-8-Drug Profile 66
    ibodutant-Drug Profile 67
    IMSUTMR-1501-Drug Profile 68
    infectious diarrhea [serotype H11] vaccine-Drug Profile 69
    LJN-452-Drug Profile 70
    octreotide acetate-Drug Profile 71
    octreotide acetate MAR-Drug Profile 72
    ondansetron hydrochloride CR-Drug Profile 73
    ORP-101-Drug Profile 80
    Peptide to Activate NHE-3 for Diarrhea-Drug Profile 81
    PF-06425090-Drug Profile 82
    prulifloxacin-Drug Profile 84
    PZ-7475-Drug Profile 86
    RBX-2660-Drug Profile 87
    RDX-023-Drug Profile 91
    RDX-98940-Drug Profile 92
    RECCE-355-Drug Profile 93
    Recombinant Enzyme for Diarrhea-Drug Profile 94
    ribaxamase-Drug Profile 95
    ridinilazole-Drug Profile 101
    rifamycin CR-Drug Profile 108
    Rotavac-5C-Drug Profile 111
    rotavirus [serotypes G1 G2 G3 G4 G8 G9] (hexavalent) vaccine-Drug Profile 112
    Rx-100-Drug Profile 113
    Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis-Drug Profile 115
    Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease-Drug Profile 116
    Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea-Drug Profile 117
    SYN-006-Drug Profile 118
    SYN-007-Drug Profile 119
    thuricin CD-Drug Profile 120
    Typhetec-Drug Profile 121
    Vaccine 1 for Diarrhea-Drug Profile 122
    Vaccine 2 for Diarrhea-Drug Profile 123
    Vaccine for Traveler's Diarrhea-Drug Profile 124
    Vaccine for Traveler's Diarrhea-Drug Profile 125
    Yersinia pestis vaccine-Drug Profile 126
    Diarrhea-Dormant Projects 127
    Diarrhea-Discontinued Products 130
    Diarrhea-Product Development Milestones 131
    Featured News & Press Releases 131
    Appendix 141
    Methodology 141
    Coverage 141
    Secondary Research 141
    Primary Research 141
    Expert Panel Validation 141
    Contact Us 141
    Disclaimer 142

    List of Tables

    Number of Products under Development for Diarrhea H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Target H2 2017 (Contd..1) H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Diarrhea-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl H2 2017
    Diarrhea-Pipeline by Actelion Ltd H2 2017
    Diarrhea-Pipeline by Aegis Therapeutics LLC H2 2017
    Diarrhea-Pipeline by Akthelia Pharmaceuticals Ltd H2 2017
    Diarrhea-Pipeline by Albireo Pharma Inc H2 2017
    Diarrhea-Pipeline by Allergan Plc H2 2017
    Diarrhea-Pipeline by Anatara Lifesciences Limited H2 2017
    Diarrhea-Pipeline by Ardelyx Inc H2 2017
    Diarrhea-Pipeline by Assembly Biosciences Inc H2 2017
    Diarrhea-Pipeline by AzurRx BioPharma Inc H2 2017
    Diarrhea-Pipeline by Bharat Biotech International Ltd H2 2017
    Diarrhea-Pipeline by Cosmo Pharmaceuticals NV H2 2017
    Diarrhea-Pipeline by DiscoveryBiomed Inc H2 2017
    Diarrhea-Pipeline by GP Pharm SA H2 2017
    Diarrhea-Pipeline by Miyarisan Pharmaceutical Company Ltd H2 2017
    Diarrhea-Pipeline by Mucosis BV H2 2017
    Diarrhea-Pipeline by Napo Pharmaceuticals Inc H2 2017
    Diarrhea-Pipeline by Nippon Shinyaku Co Ltd H2 2017
    Diarrhea-Pipeline by Novartis AG H2 2017
    Diarrhea-Pipeline by Pfizer Inc H2 2017
    Diarrhea-Pipeline by Prokarium Ltd H2 2017
    Diarrhea-Pipeline by Rebiotix Inc H2 2017
    Diarrhea-Pipeline by Recce Ltd H2 2017
    Diarrhea-Pipeline by RedHill Biopharma Ltd H2 2017
    Diarrhea-Pipeline by RxBio Inc H2 2017
    Diarrhea-Pipeline by Scandinavian Biopharma Holding AB H2 2017
    Diarrhea-Pipeline by Sigmoid Pharma Ltd H2 2017
    Diarrhea-Pipeline by Summit Therapeutics Plc H2 2017
    Diarrhea-Pipeline by Synthetic Biologics Inc H2 2017
    Diarrhea-Pipeline by Syntiron LLC H2 2017
    Diarrhea-Pipeline by Tasly Pharmaceutical Group Co Ltd H2 2017
    Diarrhea-Pipeline by Wuhan Institute of Biological Products Co Ltd H2 2017
    Diarrhea-Dormant Projects H2 2017
    Diarrhea-Dormant Projects H2 2017 (Contd..1) H2 2017
    Diarrhea-Dormant Projects H2 2017 (Contd..2) H2 2017
    Diarrhea-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Diarrhea H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Top 10 Molecule Types H2 2017
    Number of Products by Stage and Top 10 Molecule Types H2 2017
    A. Menarini Industrie Farmaceutiche Riunite Srl
    Actelion Ltd
    Aegis Therapeutics LLC
    Akthelia Pharmaceuticals Ltd
    Albireo Pharma Inc
    Allergan Plc
    Anatara Lifesciences Limited
    Ardelyx Inc
    Assembly Biosciences Inc
    AzurRx BioPharma Inc
    Bharat Biotech International Ltd
    Cosmo Pharmaceuticals NV
    DiscoveryBiomed Inc
    GP Pharm SA
    Miyarisan Pharmaceutical Company Ltd
    Mucosis BV
    Napo Pharmaceuticals Inc
    Nippon Shinyaku Co Ltd
    Novartis AG
    Pfizer Inc
    Prokarium Ltd
    Rebiotix Inc
    Recce Ltd
    RedHill Biopharma Ltd
    RxBio Inc
    Scandinavian Biopharma Holding AB
    Sigmoid Pharma Ltd
    Summit Therapeutics Plc
    Synthetic Biologics Inc
    Syntiron LLC
    Tasly Pharmaceutical Group Co Ltd
    Wuhan Institute of Biological Products Co Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//diarrhea-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//diarrhea-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//diarrhea-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments